PharmAthene finds backers for research pact

PharmAthene has gained some powerful support in Washington for its plans to expand a herd of genetically modified goats used in drug research by housing the animals at a USDA facility in Maryland. One of the state's senators, Benjamin Cardin, has introduced a measure in the farm bill that would permit just that in a public-private partnership. PharmAthene has been developing Protexia--a therapy produced in goats' milk and used to protect people from nerve agents--under Project BioShield. PharmAthene is also in a race to produce a new anthrax vaccine, a field where Human Genome Sciences is widely considered the leader.

- read the report from The Washington Post

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.